Arnulf, Bertrand <br/><br/>
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.  [electronic resource] 

 -  Haematologica  Dec 2012 
 - 1925-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1592-8721 
<br/><br/><label>Standard No.: </label>10.3324/haematol.2012.067793  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--therapeutic use<br/>Boronic Acids--therapeutic use<br/>Bortezomib<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Injections, Intravenous<br/>Injections, Subcutaneous<br/>Male<br/>Multiple Myeloma--drug therapy<br/>Neoplasm Recurrence, Local--drug therapy<br/>Prognosis<br/>Pyrazines--therapeutic use<br/>Remission Induction<br/>Survival Rate